|
CA2794153C
(en)
|
2010-03-25 |
2018-01-02 |
Glaxosmithkline Llc |
Substituted indoline derivatives as perk inhibitors
|
|
WO2012158123A1
(en)
*
|
2011-05-13 |
2012-11-22 |
Agency For Science, Technology And Research |
Compounds and methods for treating insulin resistance syndrome
|
|
EP2548877A1
(en)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
|
AU2012285987C1
(en)
|
2011-07-19 |
2016-09-08 |
Merck Sharp & Dohme B.V. |
4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as Btk- inhibitors
|
|
EP2903615B1
(en)
|
2012-10-05 |
2021-04-07 |
Merck Sharp & Dohme Corp. |
5-pyridin-3-yl-2,3-dihydro-1h-indole derivatives as aldosterone synthase (cyp11b2) inhibitors for the treatment of hypertension
|
|
MX2015009270A
(es)
*
|
2013-01-18 |
2015-10-30 |
Hoffmann La Roche |
Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
|
|
ES2638317T3
(es)
*
|
2013-04-04 |
2017-10-19 |
Janssen Pharmaceutica Nv |
Nuevos derivados de N-(2,3-dihidro-1H-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina y N-(2,3-dihidro-1H-indol-5-il)-4-quinazolinamina como inhibidores de PERK
|
|
TWI482757B
(zh)
*
|
2013-10-07 |
2015-05-01 |
Luminescence Technology Corp |
Ｖｅｇｆ－２／３受體及蛋白質酪胺酸激酶抑制劑及其醫藥用途
|
|
WO2015056180A1
(en)
*
|
2013-10-15 |
2015-04-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Indoline derivatives as inhibitors of perk
|
|
EA201691169A1
(ru)
|
2013-12-05 |
2016-09-30 |
Асерта Фарма Б.В. |
Терапевтическая комбинация ингибитора pi3k и ингибитора btk
|
|
US10272083B2
(en)
|
2014-01-21 |
2019-04-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
|
|
EP3116877A1
(en)
*
|
2014-03-11 |
2017-01-18 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Chemical compounds acting as perk inhibitors
|
|
WO2015181633A2
(en)
|
2014-04-11 |
2015-12-03 |
Acerta Pharma B.V. |
Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
|
TW201613644A
(en)
|
2014-06-17 |
2016-04-16 |
Acerta Pharma Bv |
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor
|
|
RS62713B1
(sr)
|
2014-08-11 |
2022-01-31 |
Acerta Pharma Bv |
Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
|
|
AR102426A1
(es)
|
2014-10-24 |
2017-03-01 |
Bristol Myers Squibb Co |
Compuestos de indolcarboxamida como inhibidores de btk
|
|
KR102562866B1
(ko)
|
2014-11-14 |
2023-08-04 |
네르비아노 메디칼 사이언시스 에스.알.엘. |
단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체
|
|
WO2016126026A2
(ko)
*
|
2015-02-04 |
2016-08-11 |
서울대학교병원 |
당뇨병 치료 조성물 및 이의 용도
|
|
RU2018103913A
(ru)
|
2015-07-02 |
2019-08-02 |
Асерта Фарма Б.В. |
Твердые формы и композиции (s)-4-(8-амино-3-(1-(бут-2- иноил)пирролидин-2-ил)имидазо[1,5-a]пиразин-1-ил)-n-(пиридин-2-ил)бензамида
|
|
TW201722957A
(zh)
*
|
2015-09-15 |
2017-07-01 |
葛蘭素史克智慧財產（第二）有限公司 |
化學化合物
|
|
WO2017046739A1
(en)
*
|
2015-09-15 |
2017-03-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Imidazolidinone derivatives as inhibitors of perk
|
|
CN113549110B
(zh)
*
|
2016-04-07 |
2024-08-16 |
葛兰素史密斯克莱知识产权发展有限公司 |
用作蛋白质调节剂的杂环酰胺
|
|
EP3442980B1
(en)
*
|
2016-04-15 |
2021-06-09 |
Cancer Research Technology Limited |
Heterocyclic compounds as ret kinase inhibitors
|
|
US11026945B2
(en)
*
|
2016-04-29 |
2021-06-08 |
The Trustees Of The University Of Pennsylvania |
Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation
|
|
US10723706B2
(en)
|
2016-06-13 |
2020-07-28 |
Ramot At Tel-Aviv University Ltd. |
Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins
|
|
MX388660B
(es)
|
2016-06-21 |
2025-03-20 |
Nerviano Medical Sciences Srl |
DERIVADOS DE N-(SUSTITUIDA-FENIL)-SULFONAMIDA COMO INHIBIDORES DE QUINASA N-(sustituida-fenil)-sulfonamida.
|
|
AU2017300123A1
(en)
*
|
2016-07-20 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as PERK inhibitors
|
|
CN109982693A
(zh)
*
|
2016-09-22 |
2019-07-05 |
香港大学 |
细胞异常分化和isr相关疾病的预防和治疗方法
|
|
WO2018138358A1
(en)
|
2017-01-30 |
2018-08-02 |
Université de Liège |
Perk and ire-1a inhibitors against neurodevelopmental disorders
|
|
CN106974910B
(zh)
*
|
2017-03-02 |
2019-11-12 |
深圳大学 |
含索拉非尼和gsk2656157的药物组合物及用途
|
|
CN106963769B
(zh)
*
|
2017-03-03 |
2019-10-25 |
深圳大学 |
含pi3k抑制剂和perk抑制剂的药物组合物及其应用
|
|
HUE069999T2
(hu)
|
2017-03-06 |
2025-04-28 |
Tsubota Lab Inc |
Kompozíció miópia megelõzésében vagy szuppressziójában történõ alkalmazásra
|
|
EP3680241A1
(en)
*
|
2017-03-20 |
2020-07-15 |
Forma Therapeutics, Inc. |
Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
|
|
WO2019021208A1
(en)
*
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
JP2021501785A
(ja)
|
2017-11-02 |
2021-01-21 |
カリコ ライフ サイエンシーズ エルエルシー |
統合的ストレス経路の調節剤
|
|
CN108003163B
(zh)
*
|
2017-11-30 |
2020-11-24 |
武汉九州钰民医药科技有限公司 |
用作激酶抑制剂的吡唑并嘧啶类化合物及其应用
|
|
CN111100130B
(zh)
*
|
2018-10-29 |
2022-07-15 |
四川大学 |
4-氨基吡咯并嘧啶衍生物及其制备方法和用途
|
|
CN111213632B
(zh)
*
|
2019-11-19 |
2022-03-01 |
长春中医药大学 |
动物药环氧树脂标本制作方法
|
|
CA3186041A1
(en)
|
2020-06-08 |
2021-12-16 |
Halia Therapeutics, Inc. |
Inhibitors of nek7 kinase
|
|
US20240100172A1
(en)
|
2020-12-21 |
2024-03-28 |
Hangzhou Jijing Pharmaceutical Technology Limited |
Methods and compounds for targeted autophagy
|
|
US20240382488A1
(en)
|
2021-03-29 |
2024-11-21 |
Halia Therapeutics, Inc. |
Nek7 inhibitors
|
|
KR20230175222A
(ko)
|
2021-04-05 |
2023-12-29 |
할리아 테라퓨틱스, 인코포레이티드 |
Nek7 억제제
|
|
WO2023034236A1
(en)
*
|
2021-08-31 |
2023-03-09 |
Wisconsin Alumni Research Foundation |
Deuterated inhibitors of rip kinases
|
|
GB202407386D0
(en)
|
2024-05-24 |
2024-07-10 |
Apollo Ap45 Ltd |
1H-pyrazolo(4,3-D)pyrimidine derivatives
|